This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Products

Anoro Ellipta
(umeclidinium/vilanterol inhalation powder)

Avamys
(fluticasone furoate)

Bexsero
(meningococcal groupB vaccine (rDNA, component, adsorbed))

Dovato
(dolutegravir/lamivudine)

Duac
(benzoyl peroxide/clindamycin phosphate)

Ellipta inhaler

Imigran
(sumatriptan)

Incruse Ellipta
(umeclidinium bromide)

Juluca
(dolutegravir/rilpivirine)

Nucala
(mepolizumab)

Relvar Ellipta
(fluticasone furoate/vilanterol)

Rotarix
(rotavirus vaccine)

Tivicay

(dolutegravir)

TrelegyEllipta
(fluticasone furoate/umeclidinium/vilanterol)

Triumeq
(dolutegravir/abacavir/lamivudine)

Volibris
(ambrisentan)

Vocabria Film-Coated Tablets
(cabotegravir) 
HIV

Vocabria Suspension for Injection
(cabotegravir) | VOCABRIA (cabotegravir) prolonged-release suspension for injection should always be prescribed with REKAMBYS (rilpivirine long acting). REKAMBYS, including trademark, is owned by Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare Group of Companies. Full prescribing information is available at www.ema.europa.eu
HIV

Zyban
(bupropion hydrochloride)

Therapy areas

Respiratory

Urology

Vaccines

HIV

Dermatology

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the GSK group of companies.